» Articles » PMID: 27909463

Synthetic Nanoparticles for Delivery of Radioisotopes and Radiosensitizers in Cancer Therapy

Overview
Specialty Biotechnology
Date 2016 Dec 3
PMID 27909463
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Radiotherapy has been, and will continue to be, a critical modality to treat cancer. Since the discovery of radiation-induced cytotoxicity in the late 19th century, both external and internal radiation sources have provided tremendous benefits to extend the life of cancer patients. Despite the dramatic improvement of radiation techniques, however, one challenge persists to limit the anti-tumor efficacy of radiotherapy, which is to maximize the deposited dose in tumor while sparing the rest of the healthy vital organs. Nanomedicine has stepped into the spotlight of cancer diagnosis and therapy during the past decades. Nanoparticles can potentiate radiotherapy by specifically delivering radionuclides or radiosensitizers into tumors, therefore enhancing the efficacy while alleviating the toxicity of radiotherapy. This paper reviews recent advances in synthetic nanoparticles for radiotherapy and radiosensitization, with a focus on the enhancement of in vivo anti-tumor activities. We also provide a brief discussion on radiation-associated toxicities as this is an area that, up to date, has been largely missing in the literature and should be closely examined in future studies involving nanoparticle-mediated radiosensitization.

Citing Articles

Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy.

Li H, Gong Y, Yan P, Xu Y, Qin G, Wen W Front Immunol. 2024; 15:1453753.

PMID: 39676875 PMC: 11638222. DOI: 10.3389/fimmu.2024.1453753.


Assembling a new generation of radiopharmaceuticals with supramolecular theranostics.

Moreno-Alcantar G, Drexler M, Casini A Nat Rev Chem. 2024; 8(12):893-914.

PMID: 39468298 DOI: 10.1038/s41570-024-00657-4.


Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy.

He M, Cao Y, Chi C, Zhao J, Chong E, Chin K Front Immunol. 2023; 14:1265751.

PMID: 37795091 PMC: 10545965. DOI: 10.3389/fimmu.2023.1265751.


Application of nanomedicine in radiotherapy sensitization.

Song X, Sun Z, Li L, Zhou L, Yuan S Front Oncol. 2023; 13:1088878.

PMID: 36874097 PMC: 9977159. DOI: 10.3389/fonc.2023.1088878.


Evaluation of Therapeutic Efficacy and Imaging Capabilities of SmO-Loaded Polystyrene Microspheres for Intra-Tumoural Radionuclide Therapy of Liver Cancer Using Sprague-Dawley Rat Model.

Tan H, Wong Y, Kasbollah A, Md Shah M, Yahya N, Abdullah B Pharmaceutics. 2023; 15(2).

PMID: 36839858 PMC: 9958749. DOI: 10.3390/pharmaceutics15020536.


References
1.
Melancon M, Zhou M, Li C . Cancer theranostics with near-infrared light-activatable multimodal nanoparticles. Acc Chem Res. 2011; 44(10):947-56. PMC: 3196765. DOI: 10.1021/ar200022e. View

2.
Anderson C, Welch M . Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem Rev. 2001; 99(9):2219-34. DOI: 10.1021/cr980451q. View

3.
Black K, Wang Y, Luehmann H, Cai X, Xing W, Pang B . Radioactive 198Au-doped nanostructures with different shapes for in vivo analyses of their biodistribution, tumor uptake, and intratumoral distribution. ACS Nano. 2014; 8(5):4385-94. PMC: 4358630. DOI: 10.1021/nn406258m. View

4.
Camera L, Kinuya S, Garmestani K, Wu C, Brechbiel M, Pai L . Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med. 1994; 35(5):882-9. View

5.
Radovic M, Calatayud M, Goya G, Ibarra M, Antic B, Spasojevic V . Preparation and in vivo evaluation of multifunctional ⁹⁰Y-labeled magnetic nanoparticles designed for cancer therapy. J Biomed Mater Res A. 2014; 103(1):126-34. DOI: 10.1002/jbm.a.35160. View